Meeting
2018 ASCO Annual Meeting
Safety, dose tolerance, pharmacokinetics and pharmacodynamics study of CPX-POM in patients with advanced solid tumors.
Authors
Scott James Weir
University of Kansas Cancer Center, Westwood, KS
Scott James Weir , Robyn Wood , Tammy Ham , Rashida Challenger , Prabhu Ramamoorthy , Greg Reed , Michael Jay Baltezor , Roy A. Jensen , John Arthur Taylor III, Shrikant Anant , Michael Dalton , Michael J McKenna , Valentina Zhukova-Harrill , William McCulloch , Howard A. Burris III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT03348514
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS2618)
DOI
10.1200/JCO.2018.36.15_suppl.TPS2618
Abstract #
TPS2618
Poster Bd #
433a
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Safety, dose tolerance, pharmacokinetics, and pharmacodynamics of fosciclopirox (CPX-POM) in patients with advanced solid tumors.
First Author: Manish R. Patel
Poster
2015 ASCO Annual Meeting
First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737).
First Author: Philippe L. Bedard
Poster
2014 ASCO Annual Meeting
A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fumagillol derivative, in patients (pts) with advanced solid tumors.
First Author: Johanna C. Bendell
Poster
2013 ASCO Annual Meeting
A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.
First Author: Alan Hilary Calvert